Author + information
- Received October 27, 1995
- Revision received February 29, 1996
- Accepted March 4, 1996
- Published online July 1, 1996.
- Wiek H. van Gilst, PhD1,║,†,
- J. Herre Kingma, MD∗,‡,
- Kathinka H. Peels, MD§,
- Jan-Henk E. Dambrink, MD‡ and
- Martin St.John Sutton, MB, FRCP║
- ↵1Address for correspondence: Dr. Wiek H. van Gilst, CATS Coordination Center, St. Antonius Hospital, P.O. Box 2500, 3430 EM Niewegein, The Netherlands.
Objectives. In this study we sought to investigate the effect of intervention with captopril within 6 h of the onset of myocardial infarction on left ventricular volume and clinical symptoms of heart failure in relation to infarct size during a 1-year follow-up period.
Background. Remodelling of the heart starts in the early phase of myocardial infarction and is associated with an adverse prognosis. Angiotensin-converting enzyme inhibition started in the subacute or late phase after myocardial infarction has been shown to improve prognosis.
Methods. In the Captopril and Thrombolysis Study, 298 patients with a first anterior myocardial infarction treated with intravenous streptokinase were randomized to recieve either oral captopril (25 mg three times a day) or placebo. The left ventricular volume index was assessed by two-dimensional echocardiography within 24 h, on days 3, 10 and 90 and after 1 year.
Results. A small but significant increase in left ventricular volume indexes was observed after 12 months. Using a random coefficient model, no significant treatment effect on left ventricular volumes could be detected. In contrast, when survival models were used, the occurrence of left ventricular dilation was significantly lower in captopril-treated patients (p = 0.018). In addition, the incidence of heart failure was lower in the captopril group (p < 0.03). This effect appeared early and was most obvious in patients with a medium-sized infarct (p = 0.04) and was not present in large infarcts.
Conclusions. Very early treatment with captopril after myocardial infarction significantly reduces the occurrence of early dilation and the progression to heart failure. These data underscore the importance of early treatment. Furthermore, patients with intermediate infarct size benefit the most from this treatment strategy.
- Received October 27, 1995.
- Revision received February 29, 1996.
- Accepted March 4, 1996.